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Abstract 
The function of a placebo control in a randomised trial is to permit blinding and reduce risk 
of bias. Adopting Grűnbaum’s definitional scheme of a placebo, all treatments must be 
viewed as packages consisting of characteristic and incidental features. An adequate placebo 
for an experimental treatment contains none of the characteristic features, all of the 
incidental features, and nothing more. For drug treatments, characteristic features can be 
readily identified, isolated, and separated. By contrast, physical therapy treatments often 
involve features such as patient-therapist contact and sensory feedback that make this 
separation difficult both conceptually and practically. It is therefore unsurprising that 
attempts to construct placebos for physical therapy treatments have in the past led to biased 
estimates of treatment effects. In this perspective piece, we describe the problem with 
constructing placebos for physical therapy trials drawing upon Grűnbaum’s definition and 
using paradigmatic examples from existing literature. We conclude by submitting that in the 
many cases where an adequate placebo cannot be achieved, alternative trial designs, e.g. 
dose-response or comparative-effectiveness trials, carry a lower risk of bias and should be 
favoured. 
 
Keywords: physiotherapy, placebos, randomised trial, research methodology, science 
 3 
 
The placebo control 
The placebo controlled, randomised controlled trial is widely recognized as the gold standard 
design for providing evidence in health care [1]. Yet controversies surrounding placebos 
persist, which include issues regarding ethics [2], legality [3], mechanisms [4], and even 
whether there should be such a thing as placebo at all [5]. Here, we intend to highlight some 
of the difficulties in the design and use of placebo controls within physical therapy trials.  
Unlike placebo tablets, which can be constructed simply by removing the active or 
‘characteristic’ ingredient, physical therapy treatments are often more complex, with many 
active features that cannot be easily separated.  Based on the challenges of isolating the 
characteristic feature(s) of treatments, we explore the problem with constructing placebos 
in trials of physical therapies, drawing on philosophy of science as a basis for defining what a 
placebo is and is not. After pointing out common problems, we outline potential solutions 
using alternative designs that allow trials to remain rigorous, while at the same time 
avoiding the pitfalls introduced when using inadequate placebos. 
The primary function of a placebo control in a randomized trial is to blind investigators and 
patients so that they do not know which treatment they receive. This reduces the 
confounding effects of expectations, from the participant and others, and thus reduces bias 
[1,5].  Although the purpose of placebos is widely understood, they have proved rather 
difficult to define. Flawed definitions have included ‘an inactive or inert intervention’ [6], ‘a 
treatment that has not been proved effective’ [7], and anything ‘offered to mimic the 
treatment being tested’ [8]. Placebos are of course not inert, having proven effects [9], and 
recent neuro-psychological studies reveal a great deal about the mechanisms through which 
placebos act [10]. Including a broad statement on effectiveness in the definition of a placebo 
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is a mistake, as clearly the same treatment will act differently on different outcomes, and 
proof of effectiveness on any outcome can change over time (with emerging evidence) - so a 
placebo can become a treatment and vice versa. Philosophically, we submit that Grűnbaum 
[11,12] offers the most operationally useful conceptualization of placebo. His account 
requires that all treatments, however simple, must be viewed as packages consisting of 
characteristic and incidental features. Which features are seen as characteristic and which 
incidental is relative first to the indication for that treatment, and second to the therapeutic 
theory of the people involved in giving or receiving it. To offer illustrative examples, the 
glucose in a sugar pill might be considered characteristic if it was being used to treat 
hypoglycemia, but incidental in many other cases. Regarding therapeutic theory, the 
insertion of an acupuncture needle at the correct point along a ‘Qi’ might be characteristic, 
but this depends on which theory is followed (see [13] for further detail). Once the features 
of a treatment package have been delineated, an adequate placebo control within this 
definition [11,12] must contain: 
1. All of the incidental features of the treatment, 
2. None of the characteristic features, and  
3. Nothing more. 
In drug treatments, the characteristic features are usually readily identified, isolated, and 
separated. For example, in a Prozac tablet, fluoxetine hydrochloride is the sole characteristic 
feature and the other features (the tablet casing, bulking agent, liquid with which the tablet 
is swallowed, etc.) are incidental (Figure 1). In a trial therefore, an adequate placebo control 
must be constructed from an otherwise similar tablet, offered and consumed in the same 
way, but not containing fluoxetine hydrochloride. It should look, taste, and feel the same so 
 5 
 
that it cannot be distinguished from the experimental treatment and the expectations of the 
participants (and others) are unchanged [14]. 
Compared to tablets, the characteristic features of most physical therapy treatments are 
harder to distinguish both conceptually (what counts as incidental or characteristic?) and 
practically (how can these features be physically separated?). What would an exercise 
placebo look like for example? How could something be designed that a trial participant 
thinks is exercise, but is not?  Verbal instruction and education, patient-therapist contact, 
physical action by the patient or therapist, and sensory feedback all have potentially 
therapeutic benefit on multiple outcomes, so could be considered characteristic features, 
but otherwise are extremely difficult to imitate (Table 1). To compound this issue, physical 
therapy treatments are often more complex than a tablet, involving multiple components 
treatment that interact with each other. This deepens the problem of separating out 
characteristic and incidental features which, we argue, puts placebos of physical therapies at 
high risk of failure. This is important as inadequate placebo controls lead to unblinding, 
altered expectation, and therefore systematically biased research. 
Paradigmatic examples of biased placebos that lead to underestimates of treatment effect 
sizes  
One trial compared the effects of neck manipulation (involving neck movement which 
includes a joint preload and thrust) with a placebo technique that included therapists 
moving the neck without preloading and thrusting the joint [15]. The trial showed no 
difference in pain reduction between the groups, suggesting the treatment to be ineffective. 
However, there are reasons to believe that the treatment effect was underestimated owing 
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to the placebo used. The chosen placebo implies that the investigators have classified 
preloading and thrusting the joint as the only characteristic features of the treatment being 
tested. Nonetheless, the placebo used manual therapy-type movement and touch, and for 
both of these there is independent evidence of (non-placebo) effectiveness for treating neck 
pain [16,17]. This evidence challenges the investigator's classification of these features as 
incidental. If we are correct, then the ‘placebo’ controls used in this trial are not adequate 
‘Grünbaumian’ placebos. This is because some characteristic features of the experimental 
treatment – those with independent evidence of effectiveness – were likely preserved in the 
placebo, which fails point 2 of Grűnbaum’s criteria above. Further, new features were 
introduced into the placebo with the intent to maintain participant blinding, including a 
therapeutic table drop-segment and re-developed tissue contact to ensure adequate 
sensory feedback [15]. When additional features are unintentionally introduced to the 
placebo it fails to meet point 3 [18]. These features, characteristic or not, are potentially 
therapeutic in their own right, and could shrink the difference in effect observed between 
the experimental and placebo conditions. Use of Grunbaum’s definition here helps to 
identify these features as potential confounders, which can assist in the subsequent 
interpretation of effect estimates. 
For our next example, we draw upon two trials that compared the effects of elastic taping 
with a placebo involving elastic taping in the ‘wrong’ place [20], or without the required 
amount of tension [21]. Initially, these trials may be taken as using seemingly well-
constructed placebos, but when considered using Grunbaum's definition, the separation of 
characteristic and incidental features, particularly in relation to the therapeutic theory, is 
insufficient. The placebo designs used in these trials imply that the characteristic feature of 
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elastic taping might be its placement [20] or tape tension [21]. However, in both cases the 
investigators claim that the therapeutic (i.e. characteristic) feature of the tape was its 
elasticity. Since both trials used elastic tape in the placebo group, the putatively 
characteristic feature was preserved in the placebo group, thus failing to meet point 2 of the 
definition.  Rather than providing placebo controlled evidence for elastic taping, these trials 
demonstrate that elastic taping applied in the ‘correct’ way proved more effective than 
elastic taping applied ‘incorrectly’. In both cases, the presence of the characteristic feature in 
both treatment and control means that the benefits of elastic tape have not been tested – 
the chosen placebo design was not concordant with the therapeutic theory. This critique 
might appear academic, but trials using non-elastic tape placebos, which maintain other 
incidental features, tend to demonstrate a lack of effect [22, 23].  
Biased placebos that lead to overestimation of treatment effect sizes 
Yet another trial [19] compared the effects of motor control exercises (exercise prescription 
aimed at improving movement quality) with detuned electrotherapies (inactivated passive 
therapy units) on recovery and activity in patients with chronic low back pain. The trial 
showed a large treatment effect, but in this case there is reason to suspect the chosen 
placebo design led to an overestimate of effectiveness.  The justification for detuned 
electrotherapy as a placebo was established credibility as placebos in other settings. 
However, Grunbaum's definition clearly entails that the adequacy of a placebo is to be 
judged against the features of the experimental treatment in question [12]. Electrotherapies 
bear little resemblance to the motor control exercises being tested, so a participant in this 
trial would have experienced the characteristic and incidental effects of two altogether 
different treatments. This placebo control fails because it does not include all the incidental 
 8 
 
features of the treatment (point 1), and possess additional features to those of the 
treatment, characteristic and incidental (point 3). It therefore does not isolate the 
characteristic effects of the treatment being tested. The failure to use an adequate placebo 
could have exaggerated the benefits of motor control exercises. 
Ways forward when placebos are difficult to construct 
The fact that placebos of physical therapies are difficult to define does not imply that we 
should not conduct randomised trials of physical therapies. However, care must be taken to 
reduce the bias introduced by ‘placebo’ controls.  Part of the utility of Grunbaum’s account 
of placebos for physical therapy trials is that it requires investigators to explicitly list the 
characteristic features, relative to the condition and theory, in order to determine what 
placebos would count as legitimate, and whether these can be realised practically. If a 
placebo control is used, the placebo label alone is strongly discouraged. We urge 
investigators to report their chosen placebo in sufficient detail that it can be understood, 
appraised and replicated [5,24], which would include the procedures used, timing of 
treatment, and supporting materials such as patient hand-outs [25]. For example, in the 
taping examples [20,21] enough information is offered to learn that the characteristic 
feature of the treatment (as understood) remains in the placebo. However, there is 
remaining uncertainty around potential differences in patient education and instruction. The 
recent template for intervention description and replication (TIDieR) checklist and guide [26] 
offers a suitable framework to describe both experimental and placebo interventions. 
In cases where an adequate placebo cannot be constructed, investigators might consider 
alternative trial designs. These could include a dose-response trial in which groups would 
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receive the same treatment in different amounts [27], or a comparative effectiveness trial, 
where physical therapy is compared to an established line of treatment, such as optimal 
medical management [28]. These trial designs cannot be made blind, but unlike with 
placebo controlled trials, the comparator treatment is not compromised in an attempt to do 
so [1,18]. It becomes a case of weighing up and balancing potential biases. For example, in 
trials for patients with low back pain, a comparative effectiveness trial [29] compared 
(stratified) physiotherapy to (non-stratified) current best practice, whereas the placebo 
controlled trial compared physiotherapy to a detuned electrotherapy intervention [19]. 
Whilst the former is not placebo controlled, it offers more clinically useful information; 
patients, clinicians and policy makers wish to know how a treatment compares with other 
available options. 
In summary, adequate placebos are difficult to achieve within physical therapy trials, often 
leading to biased estimates of treatment effect. If used, placebos should be fully described 
so they can be judged against the three-fold criteria of containing; all the incidental features 
of the treatment; none of the characteristic features; and nothing more. In the many cases 
where an adequate placebo cannot be achieved, other options at lower risk of bias should 
be considered in light of probable deficiencies. 
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Figure 1. Treatments as packages of characteristic and incidental features 
 
Characteristic feature 
 Fluoxetine hydrochloride 
Incidental features 
 Bulking agents 
 Liquid with which the pill is swallowed 
 Pill casing 
 Patient beliefs and expectations 
 Treatment provider beliefs and expectations 
 Colour, shape, brand name, etc. 
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Table 1. Common features of physical therapy treatments that make adequate placebos difficult to construct 
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Includes verbal instruction / education x x x x x  x x x x x 
Includes therapist supervision x   x       x 
Requires patient-therapist physical contact  x x x  x x x x x  
Requires physical action by patient x   x   x  x x x 
Requires physical action by therapist  x x x  x x x x x  
Produces sensory feedback x x x   x x  x x  
Produces physiological response(s) x  x      x x x 
Produces cognitive response(s) x x x  x x  x    
Produces expected side effect(s) x  x   x   x  x 
